Efficacy and Safety of Vonoprazan in Dual/Triple/Quadruple Regimens Both in First‐Line and Rescue Therapy for Helicobacter pylori Eradication: A Systematic Review With Meta‐Analysis
Helicobacter · 2024
DOI: 10.1111/hel.13148 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Helicobacter, 2024. Verfasst von Belén Martínez Benito und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de M…. Hauptthemen laut MEDLINE: Helicobacter Infections, Sulfonamides, Pyrroles, Helicobacter pylori. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 117 Literaturangaben.
Abstract (Originalsprache)
Background
The efficacy of Helicobacter pylori ( H. pylori ) eradication therapies encompassing one or more antibiotics and a proton pump inhibitor (PPI) has lately decreased. Vonoprazan (VPZ), a potassium‐competitive acid blocker, provides higher gastric acid suppression than PPIs. We performed a meta‐analysis evaluating the efficacy and safety of VPZ in H. pylori eradication therapies.
Methods
Studies were searched in PubMed, Embase, and the Cochrane Library up to June 2023. Efficacy was evaluated by intention‐to‐treat analysis. Data were combined by meta‐analyzing risk differences (RD). Heterogeneity was evaluated by subgrouping.
Results
Seventy‐seven studies (24 randomized clinical trials) evaluated 44,162 patients (22,297 receiving VPZ and 21,865 PPIs). Overall VPZ efficacy was 88% (95% CI = 87%–90%): 86%, 88%, and 94% for dual/triple/quadruple‐VPZ‐containing therapies. VPZ efficacy was 87% (86%–89%) in first‐line and 90% (87%–93%) in rescue therapy. VPZ performed better than PPIs in treatment‐naïve patients (87% vs. 70%; RD = 0.13, 95% CI = 0.11–0.15) and when using triple regimens. No significant differences were observed in rescue and quadruple therapies. In patients with clarithromycin‐resistant infection, VPZ‐based therapies demonstrated an 81% efficacy (76%–85%), surpassing PPIs (76% vs. 40%; RD = 0.33, 95% CI = 0.24–0.43). For clarithromycin‐susceptible strains, VPZ efficacy was 92% (89%–95%), similar to PPIs. VPZ adverse events rate was 19% (16%–21%), comparable to PPI‐based regimens (18% vs. 13%, respectively; RD = 0.00, 95% CI = −0.01 to 0.02, p = 0.57).
Conclusions
The efficacy of VPZ‐based regimens was over 85% in all treatment combinations. In treatment‐naïve and clarithromycin‐resistant patients, VPZ performed better than PPIs. In rescue therapy, in clarithromycin‐susceptible patients or when quadruple regimens were prescribed, this advantage was not confirmed. Tolerability was similar in both regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermeda…
ORCID-Profile: Belén Martínez Benito, Olga P Nyssen, Javier P Gisbert
Zitieren
APA
Benito, B. M., Nyssen, O. P., & Gisbert, J. P. (2024). Efficacy and Safety of Vonoprazan in Dual/Triple/Quadruple Regimens Both in First‐Line and Rescue Therapy for Helicobacter pylori Eradication: A Systematic Review With Meta‐Analysis. Helicobacter. https://doi.org/10.1111/hel.13148
Vancouver
Benito BM, Nyssen OP, Gisbert JP. Efficacy and Safety of Vonoprazan in Dual/Triple/Quadruple Regimens Both in First‐Line and Rescue Therapy for Helicobacter pylori Eradication: A Systematic Review With Meta‐Analysis. Helicobacter. 2024. doi:10.1111/hel.13148
BibTeX
@article{Benito2024,
author = {Benito, Belén Martínez and Nyssen, Olga P and Gisbert, Javier P},
title = {Efficacy and Safety of Vonoprazan in Dual/Triple/Quadruple Regimens Both in First‐Line and Rescue Therapy for Helicobacter pylori Eradication: A Systematic Review With Meta‐Analysis},
journal = {Helicobacter},
year = {2024},
doi = {10.1111/hel.13148}
}
EUVIMED